Mer­ck brings Har­poon Ther­a­peu­tics and its PhI/II T cell en­gager in­to the fold for $680M

Mer­ck has struck a deal to buy Har­poon Ther­a­peu­tics for $680 mil­lion, beef­ing up its on­col­o­gy pipeline with a port­fo­lio of T cell en­gagers.

At $23 per share, Mer­ck’s of­fer comes in at a 100%-plus pre­mi­um to Har­poon’s clos­ing stock price on Fri­day. Har­poon’s share price $HARP rose af­ter Bloomberg re­port­ed about the deal talks on Sun­day and is up by 112% to $22.41 Mon­day morn­ing fol­low­ing the deal an­nounce­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER